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Abstract
Aims Poor prognosis in chronic heart failure (HF) is linked to endothelial dysfunction for which there is no speciﬁc treatment
currently available. Previous studies have shown reproducible improvements in endothelial function with cocoa ﬂavanols, but
the clinical beneﬁt of this effect in chronic HF has yet to be determined. Therefore, the aim of this study was to assess the
potential therapeutic value of a high dose of cocoa ﬂavanols in patients with chronic HF, by using reductions in N-terminal
pro-B-type natriuretic peptide (NT-proBNP) as an index of improved cardiac function.
Methods and results Thirty-two patients with chronic HF, stable on guideline-directed medical therapy, were randomized to
consume 50 g/day of high-ﬂavanol dark chocolate (HFDC; 1064mg of ﬂavanols/day) or low-ﬂavanol dark chocolate (LFDC;
88mg of ﬂavanols/day) for 4weeks and then crossed over to consume the alternative dark chocolate for a further 4weeks.
Twenty-four patients completed the study. After 4weeks of HFDC, NT-proBNP (mean decrease %± standard deviation) was sig-
niﬁcantly reduced compared with baseline (44 ± 69%), LFDC (33 ± 72%), and follow-up (41 ± 77%) values. HFDC also re-
duced diastolic blood pressure compared with values after LFDC (6.7 ± 10.1mmHg).
Conclusions Reductions in blood pressure and NT-proBNP after HFDC indicate decreased vascular resistance resulting in re-
duced left ventricular afterload. These effects warrant further investigation in patients with chronic HF.
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Introduction
The prevalence of chronic heart failure (HF) or asymptomatic
left ventricular (LV) dysfunction is estimated to be ≈4%; with
between 10 and 20% of people aged over 75 years having
some degree of HF.1 Ischaemic heart disease is the predomi-
nant cause of chronic HF.1,2 Despite improvements in patient
management through guideline-directed medical therapy
(GDMT), a progressive decline in cardiac function with high
mortality is common.1,2
Endothelial dysfunction, measured as decreased ﬂow-
mediated dilatation (FMD), is closely linked to poor prognosis
in chronic HF.3–5 Increased circulating levels of endothelin-1
(ET-1) or the proendothelin-1 precursor fragment, C-terminal
proendothelin-1 (CT-proET-1), are also predictive of mortal-
ity.5–7 This may reﬂect the degree of endothelial dysfunction
or increased ET-1 production by other tissues such as the
myocardium.8 Age-related development of endothelial dys-
function contributes to increased vascular resistance and
raised blood pressure.9 These changes are likely important
predisposing factors for the onset of symptoms of chronic
HF in the elderly.1
Treatment of endothelial dysfunction in chronic HF repre-
sents an important area needing new therapies.5 High-ﬂavanol
cocoa has potential as an adjunct to standard therapy as it in-
creases endothelium-dependent vasodilator responses in
healthy individuals as well as in patients with diabetes and cor-
onary artery disease (CAD).10–12 Flavanol-rich dark chocolate
also improves endothelial function in chronic HF.13 Whether
such effects can provide a therapeutic beneﬁt of sufﬁcient mag-
nitude in chronic HF to reduce morbidity and mortality has yet
to be evaluated.
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Here, in a pilot study, we investigated whether a high daily
dose of cocoa ﬂavanols could have therapeutic value in the
treatment of chronic HF by using NT-proBNP as a biomarker
to assess changes in cardiac function after 4week consump-
tion of high-ﬂavanol dark chocolate (HFDC).
Methods
Study design and patients
The study was a single-centre randomized double-blind placebo-
controlled investigation with a crossover design. Ethical ap-
proval was obtained from the NHS Research Ethics Service
(East London and the City Research Ethics Committee; refer-
ence number 07/Q0604/24). The study conformed to the prin-
ciples outlined in the Declaration of Helsinki. Thirty-two
patients were recruited at the Heart Failure Clinic of the Lon-
don Chest Hospital. All patients had documented evidence of
previous ischaemic heart disease using invasive coronary angi-
ography and/or non-invasive testing. Patient criteria were as
follows: (i) chronic HF due to LV systolic dysfunction conﬁrmed
by transthoracic echocardiography or left ventriculogram, with
an NYHA functional classiﬁcation of 2 or 3 (ejection fraction
values were obtained from patient records), and (2) stable
for at least 6months on optimal GDMT, in accordance with
the National Institute of Clinical Excellence guidelines for
chronic HF 2003.14
The exclusion criteria were as follows: age <45 years; dia-
betes mellitus; LV dysfunction not related to systolic HF or
ischaemic heart disease; exertional angina; atrial ﬁbrillation;
cardiac surgery, percutaneous coronary intervention, acute
coronary syndrome, or stroke within 6months of the study;
active psychiatric or psychological illness; life expectancy
<1 year because of unrelated disease; anticipated compliance
issues; concurrent participation in other clinical investigations,
whether active or in follow-up; anaemia (Hb <10g/dL); abnor-
mal electrolytes or creatinine >200μmol/L; anticoagulation
therapy; chronic obstructive pulmonary disease; and treat-
ment with aminophylline or theophylline.
Patient records were screened for eligibility. Potential par-
ticipants were informed of the study. Those electing to
participate gave written informed consent before baseline
assessment and randomization to either HFDC (50 g/day) or
placebo low-ﬂavanol dark chocolate (LFDC, 50 g/day) for
4weeks. At the end of this period, patients were crossed over
to receive the other chocolate for 4weeks. Follow-up assess-
ment was undertaken 4weeks after chocolate consumption
had ceased. Four-week intervals between measurements
were used to ensure that any changes in plasma lipid proﬁles
reached steady state,15 and because 4week consumption of
high-ﬂavanol cocoa produces a sustained improvement in en-
dothelial function.11
Dark chocolate products and randomization
High-ﬂavanol dark chocolate and LFDC of similar taste and
appearance were manufactured by Barry Callebaut (Lebbeke-
Wieze, Belgium) (Table 1 shows relative compositions). Flavanol
doses for LFDC (88mg/day) and HFDC (1064mg/day) were
chosen based on previous studies showing that ≈80mg of total
ﬂavanols/day was without signiﬁcant effect on endothelial
function, while large doses of ≈900mg/day produced a consis-
tent and marked increased in endothelium-dependent ﬂow-
mediated vasodilatation.11
Chocolate was supplied as separate patient-coded boxes for
each phase of the study (50g bars ×28/box, plain foil wrapped).
Investigators were blinded to the randomization schedule. Pa-
tients were instructed to consume 25g each morning and 25g
in the afternoon, to maintain their normal dietary habits, but
not to drink red wine or take herbal medicines for HF, such as
hawthorn extract.
Patient examination and assessment
Patients underwent a physical examination with a 12-lead
ECG recording at baseline to ensure the absence of
arrhythmias. Patient details and drug treatment were re-
corded. The following measurements were made at baseline
and at 4, 8, and 12weeks: NYHA assessment, body weight,
blood pressure measured using an Omron BP Monitor
705CP II, and radial artery tonometry performed with pulse
waveform analysis using the Sphygmocor Px Model and the
accompanying software package. Blood samples were col-
lected for measurement of NT-proBNP, CT-proET-1, platelet
Table 1 Composition of high-ﬂavanol and low-ﬂavanol dark choco-
late bars
HFDC LFDC
Total cocoa solids (%) 65 65
Flavanols:
Monomers, mg 223 23
Procyanidin dimers, mg 192 24
Procyanidin trimers to decamers, mg 649 41
Total ﬂavanols (monomers to decamers), mg 1064 88
Theobromine, mg 395 420
Caffeine, mg 35 35
Total fat, g 19.9 18.8
Saturated, g 12.4 11.7
Monounsaturated, g 6.9 6.6
Polyunsaturated, g 0.6 0.5
Total protein, g 2.8 2.9
Available carbohydrates, g 18.2 18.8
Sugars, g 15.8 16.4
Starch, g 2.4 2.4
Dietary ﬁbre, g 3.0 3.1
Calories, kcal 264 257
HFDC, high-ﬂavanol dark chocolate; LFDC, low-ﬂavanol dark
chocolate.
Values are per 50 g bar (the daily amount consumed during the
HFDC and LFDC phases of the study).
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function, high-sensitivity C-reactive protein (CRP), high-
sensitivity cardiac troponin I, theobromine, lipid proﬁle (total
cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides),
HbA1c, and standard haematological and biochemical parame-
ters. Participants also completed a Quality of Life Question-
naire (SF-36v2™ Health Survey © 1992–2002 from Health
Assessment Lab, Medical Outcomes Trust and QualityMetric
Incorporated).
Blood samples for measuring NT-proBNP and CT-proET-1
were taken after patients had been at rest for at least
15min into pre-chilled EDTA tubes, placed on ice and centri-
fuged within 10min using a cooled centrifuge (2000 g for
10min at +4°C). Plasma was stored at 80°C until immunoas-
say. NT-proBNP levels were measured by high-sensitivity
electrochemiluminescent sandwich immunoassay (Meso
Scale Diagnostics, Gaithersburg, MD, USA). CT-proET-1 was mea-
sured by sandwich ELISA following published methods,16 with
afﬁnity-puriﬁed sheep IgG speciﬁc for preproET-1[169–179] as
the capture antibody and biotinylated afﬁnity-puriﬁed sheep
IgG speciﬁc for preproET-1[204–212] as the detection antibody.
CT-proET-1 assay standard was synthetic preproET-1[169–212] syn-
thesized at the DBSB Core Facility, Faculty of Medicine, Univer-
sity of Geneva (Switzerland). High-sensitivity cardiac troponin I
was measured by sandwich ELISA (HyTest, Turku, Finland). CRP
immunoassay was from MP Biomedicals (Orangeburg, NY,
USA). Plasma theobromine and caffeine levels were measured
by high-performance liquid chromatography to conﬁrm choco-
late consumption.17
Platelet function was assessed using a Platelet Function
Analyzer (PFA-100TM; Dade Behring, West Sacramento, CA, USA),
which measures shear stress-induced platelet aggregation using
both collagen–epinephrine and collagen–adenosine diphosphate
(ADP) cartridges. Results are reported as closure times indicating
the speed for blood to clot up to a maximum time of 300s.18
Statistical analyses
Twenty-four patients completed the study (Figure 1). How-
ever, only 20 patients had pulse waveform recordings of a
sufﬁcient quality index (>80%) at all time points for inclu-
sion in the analyses of haemodynamic indices derived from
pulse waveform-derived measurements. The Quality of Life
Questionnaire was completed by only 19 participants at
every time point. Data were analysed with MiniTab or
GraphPad Prism software. NT-proBNP data were subjected
to nonparametric analyses using the Friedman test followed
by Wilcoxon signed-rank test. Statistical differences for all
other data were analysed by analysis of variance with post
hoc comparison of differences between HFDC and the other
time points using Fisher’s least signiﬁcant difference test. Pa-
tient data are reported as mean ± standard deviation unless
otherwise indicated.
Results
Patient characteristics, study compliance, and
tolerability
Thirty-two patients were enrolled in the study, of which 24
completed all phases (Figure 1; patient characteristics are
shown in Table 2). Ischaemic heart disease was the
aetiology of HF in all patients. All patients were treated
with an angiotensin-converting enzyme inhibitor (ACE-I)
or an angiotensin receptor blocker and a beta-blocker
(except for one). Approximately half were treated with
diuretics. The majority of patients were also taking aspirin
and a statin.
Eight of the 32 patients initially enrolled dropped out for a
variety of reasons (withdrawals: up to 4weeks—unpalatable
taste of chocolate, LFDC n = 1, and HFDC n = 2; other LFDC
n = 2, one fall, and one unscheduled gastrointestinal surgery;
and 4–8weeks, LFDC n = 1 conﬂicting personal commitments,
HFDC n = 2, one episode of vomiting after 2weeks of HFDC,
and one planned surgery). Several patients reported mild
gastrointestinal side effects while consuming dark chocolate
Figure 1 Flow diagram illustrating study design with the number of pa-
tients entering and completing each phase of the study. HFDC, high-
ﬂavanol dark chocolate; LFDC, low-ﬂavanol dark chocolate.
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including loose stools or diarrhoea (LFDC n = 2; HFDC n = 6).
Four patients who completed the study complained about
the taste of the test products and found it difﬁcult to eat
50 g per day. One patient had swollen ankles during the ﬁrst
4weeks while consuming LFDC and had her dose of diuretic
increased by her GP. One patient reported paraesthesia in
the right hand after 4weeks of HFDC. One patient had an ep-
isode of troponin-negative chest pain while consuming HFDC.
Theobromine levels were increased to a similar degree after
HFDC and LFDC compared with baseline and follow-up values
(Table 3), conﬁrming consumption of chocolate over the
two 4week periods. Background levels of theobromine at
baseline and follow-up are likely due to caffeinated drink
consumption as theobromine is also a metabolite of caffeine.
Caffeine levels did not alter during the study.
Changes in N-terminal pro-B-type natriuretic peptide
Plasma NT-proBNP was signiﬁcantly lower after HFDC com-
pared with baseline (44± 69%, P= 0.016), LFDC (33± 72%,
P= 0.019), and follow-up values 4weeks after completion of
chocolate consumption (41± 77%, P= 0.004) (Figure 2). The
corresponding changes expressed as median decreases (with
interquartile range) were 271 (871), 178 (854), and 245
(744) pg/mL. The overall mean reduction in NT-proBNP after
HFDC compared with baseline, LFDC, and follow-up values
was 39± 56%, with 12 of the 24 patients showing an average
decrease ≥30% (Figure 2).
Changes in blood pressure
After 4week consumption of HFDC, brachial artery diastolic
blood pressure (DBP) was decreased compared with measure-
ments obtained after LFDC (6.7±10.1mmHg, P=<0.001)
and at baseline (3.8±9.0mmHg, P=0.045) (Table 4, Figure 2B).
For each patient, the mean decrease in DBP after HFDC com-
pared with baseline, LFDC, and follow-up was compared to
mean reductions in NT-proBNP (Figure 2C). Although the major-
ity of subjects showed an overall mean decrease in both DBP
and NT-proBNP after HFDC compared with the other time
points, these changes were not correlated (r=0.09; P=0.67).
Central DBP derived from the peripheral pressure waveform was
also reduced after HFDC comparedwith LFDC (7.0±10.7mmHg,
P = 0.002) (Table 4). Central and peripheral systolic blood
pressure (SBP) did not alter signiﬁcantly during the study.
Central and peripheral pulse pressures tended to increase
after HFDC, but these changes did not reach signiﬁcance.
Other haemodynamic indices derived from pulse waveform
analyses did not show signiﬁcant differences.
Effect on platelet function
No change in platelet function was detected using the PFA-
100TM analyzer. Low-dose aspirin has little or no effect on
platelet ADP responses measured with the PFA-100TM ana-
lyzer, whereas complete suppression of epinephrine re-
sponses, seen as non-closure (>300 s), is observed in
approximately 50% of the subjects.18 Here, 20 out of the 24
patients were treated with low-dose aspirin. Approximately
50% of aspirin-treated subjects exhibited non-closure with
epinephrine at some point in the study. HFDC did not in-
crease the frequency of non-closure with epinephrine and
had no effect on ADP responses (Table 3).
Table 2 Baseline characteristics of patients completing the study
n 24
Age (years) 70±10
Male gender 20 (80%)
Weight (kg) 85.7± 21.3
Body mass index (kg/m2) 29.6± 5.9
Systolic blood pressure (mmHg) 126.3±17.8
Diastolic blood pressure (mmHg) 71.0±9.8
Heart rate (bpm) 64.0±6.8
NYHA chronic HF class II/III 20 (80%)/4 (20%)
LVEF (%)a 31.2± 9.9
Pacemaker 2 (8.3%)
Ethnicity 18 Caucasian (75%),
5 South Asian (20.8%),
1 Afro-Caribbean (4.2%)
NT-proBNP (pg/mL) 1970±1412
Risk conditions for chronic HF, n (%):
CAD/ischaemic 21 (87.5%)
Prior MI 19 (79.2%)
Previous PCI 10 (41.7%)
Previous CABG 4 (16.7%)
Hypertension 16 (66.7%)
Smoker 3 (12.5%) current,
8 (33.3%) ex-smoker
Medication, n (%):
ACE-I/ARB 18/6 (100%)
ß-blocker 23 (95.8%)
Diuretic 13 (54.2%)
Aldosterone blocker 7 (29.2%)
Aspirin 20 (83.3%)
Statin 21 (87.5%)
Nitrate 7 (29.2%)
Amlodipine 2 (8.3%)
Nicorandil 3 (12.5%)
Thyroxine 3 (12.5%)
Amiodarone 1 (4.2%)
Omacor 1 (4.2%)
Niacin 1 (4.2%)
Dipyridamole 1 (4.2%)
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; CABG, coronary artery bypass graft; CAD, coro-
nary artery disease; HF, heart failure; LVEF, left ventricular ejection
fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-
type natriuretic peptide; NYHA, New York Heart Association; PCI,
percutaneous coronary intervention.
Data are presented as mean± standard deviation or number
(per cent).
aThere were no ejection fraction values for two patients with poor
echogenic windows that prevented accurate quantiﬁcation.
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Other measurements
No changes in circulating levels of CT-proET-1, CRP, or cardiac
troponin I were observed after HFDC compared with baseline,
LFDC, or follow-up values (Table 3). None of the haematological
or biochemical parameters that were assessed showed changes
in response to either LFDC or HFDC (Table 3). For the 19 patients
completing the Quality of Life Questionnaire at every clinic visit,
there were no changes in overall physical or mental well-being
scores or in the individual component scores (Table 3). There
was a trend for increased body weight during consumption of
dark chocolate (LFDC and HFDC) (P=0.4, Table 3).
Discussion
In this randomized crossover pilot study of patients with
chronic HF due to systolic LV dysfunction and prior history of
ischaemic heart disease, HFDC decreased NT-pro-BNP levels
and DBP. These ﬁndings indicate decreased peripheral vascular
resistance with a consequent reduction in cardiac afterload and
suggest that potential improvements in cardiac function after
consumption of ﬂavanols warrant further exploration.
Clinical relevance of the ﬁndings
Vasodilator therapy is a key component of GDMT in chronic
HF.1,2 However, hypotension, as a consequence of excessive
vasodilatation, is a frequent dose-limiting side effect. Previous
patient studies of high-ﬂavanol cocoa and dark chocolate have
reported reproducible improvements in endothelial function
with similar or somewhat lower daily amounts of ﬂavanols than
used here,11–13 but the long-term impact of improving endothe-
lium-dependent vasodilatation has yet to be determined. Here,
in patients with chronic HF whose treatment was considered
fully optimized according to current guidelines, daily consump-
tion of a high dose of cocoa ﬂavanols reduced NT-proBNP.
Consistent with a mechanism of action leading to improved
endothelial function and peripheral vasodilatation, DBP was
also reduced in this study. In comparison, SBP did not decrease
signiﬁcantly, and pulse pressure tended to increase, indicating
that cardiac output was increased after HFDC. Hence, lower
Table 3 Effects of 4week consumption of LFDC and HFDC
Baseline LFDC HFDC Follow-up
Methylxanthines
Theobromine (mg/L) 1.79±1.24 5.74±3.13* 6.70±3.98* 1.78± 1.18
Caffeine (mg/L) 2.68±2.19 2.32±1.00 2.57±1.48 2.21± 1.29
Biomarker measurements
CT-proET-1 (pmol/L) 16.3± 3.7 16.2±3.6 16.8±3.7 16.6±3.9
CRP (mg/L) 4.05±3.60 4.39±3.63 7.13±8.94 4.92± 4.24
Cardiac troponin I (ng/L) 3.06±2.65 3.06±2.49 2.89±1.91 2.93± 2.17
Platelet function (PFA-100, stimulated closure times)
ADP (s) 75.6± 18.5 76.1±12.4 73.8±16.8 84.0± 49.1
Epinephrine (s)a 182.7±74.9 177.1±68.9 169.3±83.3 176.2± 77.3
Haematological and biochemical analyses
Total cholesterol (mmol/L) 4.25±1.17 4.28±1.26 4.08±0.80 4.22± 1.15
LDL cholesterol (mmol/L) 2.14±1.18 2.20±1.04 1.97±0.65 2.15± 1.08
HDL cholesterol (mmol/L) 1.29±0.33 1.35±0.37 1.35±0.43 1.30± 0.36
Triglycerides (mmol/L) 1.75±0.87 1.70±0.79 1.68±0.77 1.66± 0.76
HbA1c % 6.03±0.46 6.05±0.52 5.98±0.49 6.01± 0.51
Na+ (mmol/L) 142.2±2.3 141.7± 2.5 141.6±2.3 141.5± 2.9
K+ (mmol/L) 4.48±0.38 4.57±0.43 4.63±0.41 4.46± 0.39
Urea (mmol/L) 8.55±3.06 8.70±3.94 8.80±3.99 8.59± 2.95
Creatinine (μmol/L) 104.7±27.7 102.3±28.6 104.3±27.6 101.9± 30.0
Alanine transaminase (IU/L) 23.8± 14.3 24.5±13.3 21.7±8.1 21.3±6.2
Hb (g/dL) 13.3± 1.6 13.2±1.6 13.1±1.4 13.1±1.4
MCV (fL) 89.1± 5.8 88.7±5.3 88.4±5.1 88.6±5.6
WBC 109/L 7.78±1.45 7.33±1.59 7.92±1.42 7.65±1.60
Platelets 109/L 243±51 243± 62 255± 70 247±63
Quality of Life Questionnaireb
Physical well-being score 36.6±10.1 36.8±10.0 37.6±10.9 36.9± 10.7
Mental well-being score 45.9±14.2 46.8±8.8 46.9±10.3 45.7± 11.8
Body weight (kg) 85.7± 21.3 86.1±20.8 86.1±20.6 85.6± 21.1
ADP, adenosine diphosphate; CRP, C-reactive protein; CT-proET-1, C-terminal proendothelin-1; HFDC, high-ﬂavanol dark chocolate; LFDC,
low-ﬂavanol dark chocolate; MCV, mean cell volume; WBC, white blood cell count.
One-way analysis of variance with Fisher’s least signiﬁcant difference test: *P< 0.001 compared with baseline or follow-up.
aClosure times exceeding 300 s were recorded as a closure time of 300 s for statistical analyses.
bn=19 for study participants completing the questionnaire at all time points.
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NT-proBNP probably reﬂects reduced LV afterload because of
decreased peripheral vascular resistance.
No changes were observed in NYHA classiﬁcation or in the
quality of life assessment of changes in physical, mental, and
social functioning. But the treatment period with HFDC is likely
too short to achieve quantiﬁable changes in these measures.
Prognostic signiﬁcance of reductions in N-terminal
pro-B-type natriuretic peptide
Plasma levels of BNP and NT-proBNP are sensitive biomarkers of
the severity of chronic HF, which predict prognosis.19 Treatment
strategies aimed speciﬁcally at reducing NT-proBNP result in
fewer cardiovascular events.20 Reductions in BNP or NT-proBNP
are associated with lower mortality, with decreases ≥30% asso-
ciated with less adverse outcomes.21 NT-proBNP decreased by
>30% in half the patients here, so adding cocoa ﬂavanols to
GDMT has potential to reduce mortality compared with stan-
dard therapy alone.
Cocoa ﬂavanols as a treatment for endothelial
dysfunction
Despite evidence that endothelial dysfunction is linked to
poor prognosis in chronic HF, there are no treatments
that speciﬁcally reverse this decline in vasodilator function.5
ACE-Is and statins produce modest improvements in endothe-
lial function.5,22 In comparison, cocoa ﬂavanols increase FMD
responses in patients with diabetes, CAD, or chronic HF even
when concurrent treatment includes these medications.11–13
Here, all patients were treated with an ACE-I or angiotensin
receptor blocker, and the majority also received statins, so
Figure 2 (A) Plasma measurements of N-terminal pro-B-type natriuretic
peptide (NT-proBNP) at baseline, after 4weeks of low-ﬂavanol dark choco-
late (LFDC), after 4weeks of high-ﬂavanol dark chocolate (HFDC), and at fol-
low-up (median with 25th and 75th percentiles). Friedman test, P = 0.017
for the effect of HFDC (individual P-values derived from Wilcoxon signed
rank test). (B) Changes in NT-proBNP (%) (red bars) and diastolic blood pres-
sure (DBP) (mmHg) (blue bars) after HFDC compared with values at base-
line, after LFDC, and at follow-up (mean ± SEM; *, **, *** = P <0.05,
<0.01, <0.001, respectively). (C) Individual patient changes in NT-proBNP
(%) plotted relative to changes in DBP (mmHg), differences (mean ± SEM)
after HFDC compared with values at baseline, after LFDC, and at follow-up.
Table 4 Blood pressure measurements
Brachial artery (n=24):
Baseline LFDC HFDC Follow-up
SBP 126.3±17.8 124.9±15.7 123.9±22.5 126.3±19.1
DBP* 71.0± 9.8 73.8±10.4 67.1±10.5,b 70.6± 10.9
PP 55.3±13.0 51.0±14.9 56.8±20.0 55.7±15.7
MBP 89.4±11.5 90.8±10.3 86.0±12.4 89.2±12.1
HR 64.0± 6.8 61.3±9.5 63.9±7.7 63.8±8.6
Derived from pulse wave analyses (n=20):
cSBP 117.1±17.5 116.2±16.3 115.3±23.5 117.8±20.3
cDBP** 71.7±11.0 74.6±11.3 67.5±11.6c 70.7± 12.1
cPP 45.4±10.9 41.7±14.8 47.8±18.8 47.5±14.7
cMBP 89.7±13.2 90.5±11.8 86.0±15.0 88.9±15.0
AIx 30.2± 9.4 28.4±10.3 29.5±12.3 30.2±12.9
c, central; DBP, diastolic blood pressure; HFDC, high-ﬂavanol dark
chocolate; HR, heart rate; LFDC, low-ﬂavanol dark chocolate; MBP,
mean blood pressure; PP, pulse pressure; SBP, systolic blood
pressure.
ValuesBP(mmHg),HR(bpm),augmentation index(AIx,%),mean±stan-
ndard deviation.
Analysis of variance: *P=0.008, **P=0.016.
Fisher’s least signiﬁcant difference test:
aBaseline versus HFDC, P=0.045,
bLFDC versus HFDC, P=<0.001,
cLFDC versus HFDC, P=0.002.
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ﬂavanol-induced changes in vascular function with reductions
in NT-proBNP are additive to that achieved by GDMT.
Endothelial dysfunction is both a cause and consequence
of HF. Flow-dependent vasodilatation is mediated by the
endothelium in response to shear stresses exerted by
ﬂowing blood on the vascular wall. Indeed, reduced reac-
tive hyperaemia is associated with low basal forearm blood
ﬂow, likely as a result of low cardiac output.4 The impor-
tance of this as a factor underlying decreased FMD re-
sponses in chronic HF is highlighted by observations that
heart transplantation can reverse endothelium-dependent
vasodilator responses.23,24 Current evidence indicates that
ﬂavanols restore ﬂow-mediated vasodilatation. In chronic
HF, this may result in reduced peripheral vascular resistance
and lower DBP, with a consequent reduction in LV afterload
leading to decreased myocardial release of NT-proBNP. We
hypothesize that ﬂavanol-induced peripheral vasodilatation
enables cardiac output to increase, so that SBP is main-
tained, which in turn further improves ﬂow-mediated vaso-
dilatation (Figure 3).
Plasma levels of ET-1 and the relatively stable big ET-1 and
CT-proET-1 (a fragment of the ET-1 precursor) are increased
in HF and predict outcome.5–7 Changes in plasma biomarkers
of ET-1 synthesis may be expected to indicate endothelial dys-
function. Cocoa ﬂavanols inhibit ET-1 synthesis by endothelial
cells (see Supporting Information Appendix S1 comparing the
effects of ﬂavanol extracts prepared from HFDC and LFDC);25
nevertheless, HFDC had no effect on circulating CT-proET-1
levels. However, the main source of plasma CT-proET-1 in
chronic HF may be the myocardium, or other vascular cells,
rather than the endothelium,8 hence limiting the potential
for CT-proET-1 as a biomarker of endothelial function. Studies
of other endothelial biomarkers (e.g. von Willebrand factor
and E-selectin) also showed no relationship with BNP.5
Effect of ﬂavanols on platelet function
Chronic HF increases platelet thrombogenicity and the risk of
thrombotic events.26 Flavanols have been reported to have
anti-platelet activity.13 In a previous study in chronic HF,
ﬂavanol-rich chocolate caused an acute reduction in shear
stress-dependent platelet adhesion, but after 4week consump-
tion, this response was lost.13 Similarly, no change in platelet
function was observed here after 4weeks of HFDC.
Optimal daily amount of ﬂavanols in patients with
chronic heart failure
Improvements in endothelial function after cocoa ﬂavanols are
dose related.11 In patients with type 2 diabetes (>70% with a
history of CAD), FMD was markedly increased after a single
cocoa drink (963mg of ﬂavanols),11 whereas the response to
371mg of ﬂavanols was substantially less and 75mg had no
effect.11 Daily treatment of diabetic patients for 1month
(321mg thrice daily) increased both basal FMD and the acute
response measured 2 h after a morning cocoa drink (321mg
of ﬂavanols).11 Similarly, 750mg of ﬂavanols/day improved
FMD responses and also decreased SBP patients with CAD,12
but <500mg/day is likely insufﬁcient as endothelial function
did not improve after 6weeks in hypercholesterolemic women
(446mg of ﬂavanols/day)27 or in another study of patients
with established CAD (444mg daily).28
In chronic HF, a ﬂavanol-rich chocolate (624mg of ﬂavanols/
day for 4weeks) increased FMD responses but did not change
BP or NT-proBNP.13 Therefore, a higher daily amount may be
required for a clinically signiﬁcant improvement in cardiac
function. Whether 1064mg of ﬂavanols/day, the amount used
here, is optimal in chronic HF requires conﬁrmation in future
dose-ranging studies.
Composition of cocoa ﬂavanols and relevance to
future clinical trials
Cocoa ﬂavanols consist of a mixture of monomers (such as
()-epicatechin), dimers, and oligomeric procyanidins (OPC),
which are mainly oligomers of ()-epicatechin ranging from tri-
mers to decamers.29 Schroeter and colleagues attributed the
increase in FMD observed in healthy volunteers after a high-
ﬂavanol cocoa drink to ()-epicatechin.10 However, puriﬁed
()-epicatechin produced only 30% of the response seen with
cocoa ﬂavanols,10 indicating that OPC play a role in this vascu-
lar effect. Here, OPC represented ≈60% of total cocoa ﬂavanols
in HFDC (Table 1). Experimentally, OPC have potent actions on
Figure 3 Schematic hypothesis for how ﬂavanols reduce N-terminal pro-
B-type natriuretic peptide (NT-proBNP) levels and improve cardiac func-
tion in chronic heart failure. Flavanols increase nitric oxide synthesis,
suppress endothelin-1 (ET-1) synthesis, and restore endothelium-medi-
ated ﬂow-dependent vasodilatation. LV, left ventricular; PVR, peripheral
vascular resistance.
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endothelial function inducing endothelium-dependent vasodi-
latation and inhibiting ET-1 synthesis.25,30,31 Currently, little is
known about the fate of OPC following oral administration.
Until it is fully understood which components of cocoa
ﬂavanols are responsible for these effects on vascular function,
it will be difﬁcult to optimize products for medical use.
Interestingly, hawthorn extract (Cretageus species), a tradi-
tional remedy for chronic HF, contains ﬂavanols mainly as
OPC.30 WS 1442 is a hawthorn extract composed of 18.75%
OPC, which causes endothelium-dependent vasodilatation of
isolated coronary arteries.32 Several clinical trials in chronic
HF have evaluated WS 1442. A dose of 1800mg/day (337mg
OPC per day) improved exercise tolerance, but half of this dose
lacked signiﬁcant functional effects.33 The lower dose (900mg
WS 1442 per day; ≈170mg OPC) was used for the SPICE trial, a
multi-centre trial in 2681 patients with chronic HF.34 At this
dose, patients with an LVEF ≥25–35% had a 39% reduction in
sudden death, but there was no change in total mortality.
Effects on NT-proBNP were not reported.34 The same dose of
WS 1442 was also used in the Hawthorn Extract Randomized
Blinded Chronic Heart Failure trial. This showed no effect on
6min walking distance, blood pressure, or BNP.35 Although
some have concluded that hawthorn extract has no beneﬁcial
effects in patients optimized to GDMT, the lack of efﬁcacy in
these trials can also be explained by the use of an ineffective
dose of WS 1442 (≈170mg OPC),34,35 compared with HFDC
(649mg OPC) used here.
Strengths and limitations
A key strength of this study is that patients were stable on
GDMT prior to enrolment so that NT-proBNP levels were fairly
constant throughout the study. The crossover design
strengthens the conclusion that the reduction in NT-proBNP
levels after HFDC compared with all other time points was
due to the ﬂavanol components. However, the absence of a
pretreatment period to assess baseline ﬂuctuations in NT-
proBNP prior to randomisation to HFDC or LFDC is a weakness
of the study design. Further limitations include the small sam-
ple size, the short period of investigation, and the absence of
FMD measurements or assessment of LV function to correlate
with blood pressure and reductions in NT-proBNP. In addition,
all patients had a history of ischaemic heart disease, which
limits the generalizability of the ﬁndings relative to the broader
spectrum of patients with chronic HF of different aetiologies.
Conclusions
This study indicates that combining cocoa ﬂavanols with GDMT
has potential for improving cardiac function in chronic HF. Dark
chocolate may not be the ideal product because of its poor
palatability and high calorie content. However, optimisation
of a ﬂavanol supplement requires identiﬁcation of the principal
active components in mixed ﬂavanol extracts that are
responsible for changes in FMD, blood pressure, and NT-
proBNP. Future studies should also determine whether the
effect on NT-proBNP is sustained and correlated with improve-
ments in LV function and exercise capacity.
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Figure S1. Inhibition of ET-1 synthesis by cultured endothelial
cells with chocolate ﬂavanol extracts prepared from HFDC
and LFDC. Extract concentrations expressed equivalent to
weight of chocolate samples. Results are mean ± SEM for ex-
tracts of two samples of each chocolate evaluated in triplicate
in two experiments.
References
1. Dickstein K, Cohen-Solal A, Filippatos
G, McMurray JJV, Ponikowski P,
Poole-Wilson PA, Strömberg A, van
Veldhuisen DJ, Atar D, Hoes AW,
Keren A, Mebazaa A, Nieminen M,
Priori SG, Swedberg K. ESC Guide-
lines for the diagnosis and manage-
ment of acute and chronic heart
failure 2008. Eur Heart J 2008; 29:
2388–2442.
2. Jessup M, Abraham WT, Casey DE,
Feldman AM, Francis GS, Ganiats TG,
Konstam MA, Mancini DM, Rahko PS,
Silver MA, Stevenson LW, Yancy CW. Fo-
cused update: ACCF/AHA Guidelines
104 R. De Palma et al.
ESC Heart Failure 2016; 3: 97–106
DOI: 10.1002/ehf2.12077
for the diagnosis and management of
heart failure in adults: A report of the
American College of Cardiology Foun-
dation/American Heart Association Task
Force on practice guidelines developed
in collaboration with the International
Society for Heart and Lung Transplanta-
tion. Circulation 2009; 119: 1977–2016.
3. Meyer B, Mörtl D, Strecker K, Hülsmann
M, Kulemann V, Neunteuﬂ T, Pacher R,
Berger R. Flow-mediated vasodilation
predicts outcome in patients with
chronic heart failure: comparison with
B-type natriuretic peptide. J Am Coll
Cardiol 2005; 46: 1011–1018.
4. de Berrazueta JR, Guerra-Ruiz A,
García-Unzueta MT, Toca GM, Laso RS,
de Adana MS, Martín MA, Cobo M,
Llorca J. Endothelial dysfunction, mea-
sured by reactive hyperaemia using
strain-gauge plethysmography, is an in-
dependent predictor of adverse outcome
in heart failure. Eur J Heart Fail 2010;
12: 477–483.
5. Shantsila E, Wrigley BJ, Blann AD, Gill
PS, Lip GY. A contemporary view on en-
dothelial function in heart failure. Eur J
Heart Fail 2012; 14: 873–881.
6. Pousset F, Isnard R, Lechat P, Kalotka H,
Carayon A, Maistre G, Escolano S,
Thomas D, Komajda M. Prognostic value
of plasma endothelin-1 in patients with
chronic heart failure. Eur Heart J 1997;
18: 254–258.
7. Masson S, Latini R, Carbonieri E, Moretti
L, Rossi MG, Ciricugno S, Milani V,
Marchioli R, Struck J, Bergmann A,
Maggioni AP, Tognoni G, Tavazzi L,
GISSI-HF Investigators. The predictive
value of stable precursor fragments of
vasoactive peptides in patients with
chronic heart failure: data from the
GISSI-heart failure (GISSI-HF) trial. Eur
J Heart Fail 2010; 12: 338–347.
8. Majak P, Bjørnstad JL, Braathen B,
Lunde IG, Husebye T, Christensen G,
Tønnessen T. Endothelin-1 in the human
myocardium and circulating plasma:
evaluation before, during and after cor-
rection of aortic stenosis with aortic
valve replacement. Cardiology 2012;
123: 1–10.
9. Lakatta EG, Levy D. Arterial and cardiac
aging: major shareholders in cardiovas-
cular disease enterprises: part I: aging
arteries: a “set up” for vascular disease.
Circulation 2003; 107: 139–146.
10. Schroeter H, Heiss C, Balzer J,
Kleinbongard P, Keen CL, Hollenberg
NK, Sies H, Kwik-Uribe C, Schmitz HH,
Kelm M. ()-Epicatechin mediates bene-
ﬁcial effects of ﬂavanol-rich cocoa on vas-
cular function in humans. Proc Natl Acad
Sci U S A 2006; 103: 1024–1029.
11. Balzer J, Rassaf T, Heiss C, Kleinbongard
P, Lauer T, Merx M, Heussen N, Gross
HB, Keen CL, Schroeter H, Kelm M.
Sustained beneﬁts in vascular function
through ﬂavanol-containing cocoa in
medicated diabetic patients a double-
masked, randomized, controlled trial. J
Am Coll Cardiol 2008; 51: 2141–2149.
12. Heiss C, Jahn S, Taylor M, Real WM,
Angeli FS, Wong ML, Amabile N, Prasad
M, Rassaf T, Ottaviani JI, Mihardja S,
Keen CL, Springer ML, Boyle A,
Grossman W, Glantz SA, Schroeter H,
Yeghiazarians Y. Improvement of endo-
thelial function with dietary ﬂavanols is
associated with mobilization of circulat-
ing angiogenic cells in patients with coro-
nary artery disease. J Am Coll Cardiol
2010; 56: 218–224.
13. Flammer AJ, Sudano I, Wolfrum M,
Thomas R, Enseleit F, Périat D, Kaiser P,
Hirt A, Hermann M, Seraﬁni M, Lévêques
A, Lüscher TF, Ruschitzka F, Noll G, Corti
R. Cardiovascular effects of ﬂavanol-rich
chocolate in patients with heart failure.
Eur Heart J 2012; 33: 2172–2180.
14. Chronic Heart Failure. National clinical
guideline for diagnosis and management
in primary and secondary care. National
Institute for Clinical Excellence. Guide-
line No. 5, 2003.
15. Kris-Etherton PM, Dietschy J. Design
criteria for studies examining individual
fatty acid effects on cardiovascular disease
risk factors: human and animal studies.
Am J Clin Nutr 1997; 65: 1590S–1596S.
16. Corder R. Evaluation of endothelin-
converting enzyme inhibitors using cul-
tured cells. Methods Mol Biol 2002;
206: 147–164.
17. Holland DT, Godfredsen KA, Page T,
Connor JD. Simple high-performance
liquid chromatography method for the
simultaneous determination of serum
caffeine and paraxanthine following
rapid sample preparation. J Chromatogr
B Biomed Sci Appl 1998; 707: 105–110.
18. Jilma B. Platelet function analyzer (PFA-
100): a tool to quantify congenital or ac-
quired platelet dysfunction. J Lab Clin
Med 2001; 138: 152–163.
19. Masson S, Latini R, Anand IS, Vago T,
Angelici L, Barlera S, Missov ED, Clerico
A, Tognoni G, Cohn JN, Val-HeFT Inves-
tigators. Direct comparison of B-type na-
triuretic peptide (BNP) and amino-
terminal proBNP in a large population
of patients with chronic and symptom-
atic heart failure: the Valsartan Heart
Failure (Val-HeFT) data. Clin Chem
2006; 52: 1528–1538.
20. Gaggin HK, Mohammed AA, Bhardwaj
A, Rehman SU, Gregory SA, Weiner
RB, Baggish AL, Moore SA, Semigran
MJ, Januzzi JL. Heart failure outcomes
and beneﬁts of NT-proBNP-guided man-
agement in the elderly: Results from the
prospective, randomized proBNP outpa-
tient tailored chronic heart failure ther-
apy (PROTECT) study. J Cardiac Fail
2012; 18: 626–634.
21. Masson S, Latini R, Anand IS, Barlera S,
Angelici L, Vago T, Tognoni G, Cohn JN,
Val-HeFT Investigators. Prognostic value
of changes in N-terminal pro-brain natri-
uretic peptide in Val-HeFT (Valsartan
Heart Failure Trial). J Am Coll Cardiol
2008; 52: 997–1003.
22. Tousoulis D, Antoniades C, Vassiliadou
C, Toutouza M, Pitsavos C, Tentolouris
C, Trikas A, Stefanadis C. Effects of com-
bined administration of low dose ator-
vastatin and vitamin E on inﬂammatory
markers and endothelial function in pa-
tients with heart failure. Eur J Heart Fail
2005; 7: 1126–1132.
23. Kubo SH, Rector TS, Bank AJ,
Tschumperlin LK, Raij L, Brunsvold N,
Kraemer MD. Effects of cardiac trans-
plantation on endothelium-dependent
dilation of the peripheral vasculature in
congestive heart failure. Am J Cardiol
1993; 71: 88–93.
24. Patel AR, Kuvin JT, Pandian NG, Smith
JJ, Udelson JE, Mendelsohn ME,
Konstam MA, Karas RH. Heart failure
etiology affects peripheral vascular en-
dothelial function after cardiac trans-
plantation. J Am Coll Cardiol 2001; 37:
195–200.
25. Caton PW, Pothecary MR, Lees DM,
Khan NQ, Wood EG, Shoji T, Kanda T,
Rull G, Corder R. Regulation of vascular
endothelial function by procyanidin-rich
foods and beverages. J Agric Food Chem
2010; 58: 4008–4013.
26. Mehta J, Mehta P. Platelet function stud-
ies in heart disease: VI. Enhanced plate-
let aggregate formation activity in
congestive heart failure: inhibition by
sodium nitroprusside. Circulation 1979;
60: 497–503.
27. Wang-Polagruto JF, Villablanca AC,
Polagruto JA, Lee L, Holt RR, Schrader
HR, Ensunsa JL, Steinberg FM, Schmitz
HH, Keen CL. Chronic consumption of
ﬂavanol-rich cocoa improves endothelial
function and decreases vascular cell ad-
hesion molecule in hypercholesterolemic
postmenopausal women. J Cardiovasc
Pharmacol 2006; 47: S177–S186.
28. Farouque HMO, Leung M, Hope SA,
Baldi M, Schechter C, Cameron JD, Mer-
edith IT. Acute and chronic effects of
ﬂavanol-rich cocoa on vascular function
in subjects with coronary artery disease:
a randomized double-blind placebo-
controlled study. Clin Sci 2006; 111:
71–80.
29. Kelm MA, Johnson JC, Robbins RJ,
Hammerstone JF, Schmitz HH. High-
performance liquid chromatography
separation and puriﬁcation of cacao
(Theobroma cacao L.) procyanidins ac-
cording to degree of polymerization
using a diol stationary phase. J Agric
Food Chem 2006; 54: 1571–1576.
30. Corder R, Warburton RC, Khan NQ,
Brown RE, Wood EG, Lees DM. The
procyanidin-induced pseudo laminar
shear stress response: new concept for
the reversal of endothelial dysfunction.
Clin Sci 2004; 107: 513–517.
31. Karim M, McCormick K, Kappagoda CT.
Effects of cocoa extracts on endothelium-
dependent relaxation. J Nutr 2000; 130:
2105S–2108S.
32. Anselm E, Socorro VFM, Dal-Ros S,
Schott C, Bronner C, Schini-Kerth VB.
Crataegus special extract WS 1442
Causes endothelium-dependent relaxa-
tion via a redox-sensitive Src- and Akt-
Cocoa ﬂavanols reduce NT-proBNP in heart failure 105
ESC Heart Failure 2016; 3: 97–106
DOI: 10.1002/ehf2.12077
dependent activation of endothelial NO
synthase but not via activation of estro-
gen receptors. J Cardiovasc Pharmacol
2009; 53: 253–260.
33. Tauchert M. Efﬁcacy and safety of
Crateagus extract WS 1442 in compari-
son with placebo in patients with
chronic stable New York Heart Associa-
tion Class III Heart Failure. Am Heart J
2002; 143: 910–915.
34. Holubarsch CJ, Colucci WS, Meinertz
T, Gaus W, Tendera M. Survival and
prognosis: investigation of Crataegus
extract WS 1442 in CHF (SPICE) trial
study group. Eur J Heart Fail 2008;
10: 1255–1263.
35. Zick SM, Vautaw BM, Gillespie B,
Aaronson KD. Hawthorn Extract Ran-
domized Blinded Chronic Heart Failure
(HERB CHF) trial. Eur J Heart Fail
2009; 11: 990–999.
106 R. De Palma et al.
ESC Heart Failure 2016; 3: 97–106
DOI: 10.1002/ehf2.12077
